AMPH Overview

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredient (API) products. Most of the Company's finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. The Company manufactures and sells over 25 prescription pharmaceutical products, and one over-the-counter product, Primatene MIST. Its marketed products include BAQSIMI (glucagon) nasal powder 3mg, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone, Cortrosyn, Amphadase, and Epinephrine injection. It manufactures and sells two API products: Recombinant Human Insulin (RHI API) and porcine insulin API. It is also focused on generic and proprietary product candidates in the injectable, inhalable, topical, and intranasal markets.

Wall Street analysts forecast AMPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMPH is32.00 USD with a low forecast of 30.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Amphastar Pharmaceuticals, Inc revenue for the last quarter amounts to 171.17M USD, increased 0.38

Amphastar Pharmaceuticals, Inc. EPS for the last quarter amounts to USD, decreased -100.00

Amphastar Pharmaceuticals, Inc (AMPH) has 1976 emplpoyees as of May 10 2026.

Today AMPH has the market capitalization of 1.07B USD.